CN1328466A - 抗真菌剂在治疗硬化中的用途 - Google Patents

抗真菌剂在治疗硬化中的用途 Download PDF

Info

Publication number
CN1328466A
CN1328466A CN99813799A CN99813799A CN1328466A CN 1328466 A CN1328466 A CN 1328466A CN 99813799 A CN99813799 A CN 99813799A CN 99813799 A CN99813799 A CN 99813799A CN 1328466 A CN1328466 A CN 1328466A
Authority
CN
China
Prior art keywords
fungus
rhodotorula
antifungal
organism
relevant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99813799A
Other languages
English (en)
Chinese (zh)
Inventor
R·安特诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANDIDA MEDICAL BV
Original Assignee
CANDIDA MEDICAL BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CANDIDA MEDICAL BV filed Critical CANDIDA MEDICAL BV
Publication of CN1328466A publication Critical patent/CN1328466A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN99813799A 1998-10-27 1999-10-27 抗真菌剂在治疗硬化中的用途 Pending CN1328466A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRPCT/FR98/02302 1998-10-27
PCT/FR1998/002302 WO2000024402A1 (fr) 1998-10-27 1998-10-27 Utilisation d'antifongiques dans le traitement des scleroses

Publications (1)

Publication Number Publication Date
CN1328466A true CN1328466A (zh) 2001-12-26

Family

ID=9523370

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99813799A Pending CN1328466A (zh) 1998-10-27 1999-10-27 抗真菌剂在治疗硬化中的用途

Country Status (8)

Country Link
EP (1) EP1124560A1 (pt)
JP (1) JP2002528064A (pt)
CN (1) CN1328466A (pt)
AU (2) AU1036999A (pt)
BR (1) BR9914792A (pt)
CA (1) CA2348160A1 (pt)
IL (1) IL142641A0 (pt)
WO (2) WO2000024402A1 (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110269939A (zh) * 2019-03-12 2019-09-24 武汉愔紫生物科技有限公司 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法
CN110343650B (zh) * 2019-05-28 2020-12-29 浙江工业大学 一种产两性霉素b的重组结节链霉菌及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE753078A (fr) * 1969-07-07 1971-01-07 Schmid Inc Julius Compositions de traitement de l'hyperlipemie
US4289757A (en) * 1978-02-28 1981-09-15 The Upjohn Company Method for treating inflammation
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
GB2290707A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of Amphotericin B
GB2290709A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of nystatin

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110269939A (zh) * 2019-03-12 2019-09-24 武汉愔紫生物科技有限公司 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法
CN110343650B (zh) * 2019-05-28 2020-12-29 浙江工业大学 一种产两性霉素b的重组结节链霉菌及其应用

Also Published As

Publication number Publication date
CA2348160A1 (fr) 2000-05-04
AU1036999A (en) 2000-05-15
EP1124560A1 (fr) 2001-08-22
AU6347199A (en) 2000-05-15
WO2000024403A1 (fr) 2000-05-04
BR9914792A (pt) 2001-11-27
JP2002528064A (ja) 2002-09-03
WO2000024402A1 (fr) 2000-05-04
IL142641A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
Sathe-Pathak et al. Thraustochytrid and fungal component of marine detritus. I-Field studies on decomposition of the brown alga Sargassum cinereum J. Ag.
CN1161021C (zh) 一种生物控制方法
CN1058341A (zh) 表面治疗损伤或罹患组织的组合物及方法
CN1328466A (zh) 抗真菌剂在治疗硬化中的用途
CN101766644A (zh) 具有抗癌效果的蘑菇多糖体组合物及其制备方法
Wood et al. Ecological observations on the fungal colonization of fish by Saprolegniaceae in Windemere
KR20150055650A (ko) 목질진흙상황버섯 자실체의 재배방법 및 이에 의해 재배된 목질진흙상황버섯 자실체
CN108315266B (zh) 蝉拟青霉及应用
CN114790438B (zh) 一种提高牛樟芝胞外多糖产量及其抗氧化性的方法
CN1513530A (zh) 一种治疗灰指甲的中药及其制备方法
CN1039384C (zh) 加速创伤愈合的组合物
TW201839124A (zh) 牛樟芝子實體之培養基及其培養方法
JPH01193269A (ja) 発酵培地中より単離された駆虫剤として活性のあるパラハークアミド誘導体
CN1327047A (zh) 一种用蚕蛹培养拟青霉菌的方法及药用用途
WO2010107294A1 (en) Antifungal compound and its production
CN113842399B (zh) 一种具有抗肿瘤活性的海洋原生动物游仆虫提取物浸膏
CN1212387C (zh) 从虫草体分离培养的细棒束孢sx－1及其培养方法和用途
CN1231220C (zh) 毛蕊花甙的新用途
CN1023567C (zh) 从金黄色葡萄球菌代谢产物中提取治疗恶性肿瘤用药的方法
TWI680756B (zh) 使用2,4-二甲氧基-6-甲基苯-1,3-二醇來防止和/或抑制葡萄球菌屬物種的生長以及生物膜形成
Wada et al. Primary lymphocutaneous nocardiosis caused by Nocardia otitidiscaviarum
Youngs et al. The penetration of fleroxacin into intra-abdominal abscesses
Ajah et al. Endophytic Fungi Isolated from Pteridium acquilinium and Newbouldia laevis Leaves Exhibited Antioxidant Activities and Inhibitory Potential Against Selected Clinical Bacteria Isolates
CN1857351A (zh) 一种抗肿瘤的药物组合物及其制备方法
ZA200309122B (en) Identifying parasitic fungi of the organism and treatment thereof.

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication